This trial is testing the safety and tolerability of teclistamab when combined with other drugs. The goal is to find the best dose of the combination.
4 Primary · 12 Secondary · Reporting Duration: Up to 2 year and 5 months
Experimental Treatment
140 Total Participants · 7 Treatment Groups
Primary Treatment: Teclistamab · No Placebo Group · Phase 1
Age 18+ · All Participants · 5 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: